Abstract: The invention provides methods for treating cancers, such as melanoma and/or metastatic melanoma, using compounds that interact with and/or inhibit cellular proteins lamin A/C, ATP-dependent RNA helicase DDX1 (DDX1), heterogeneous nuclear ribonuclear protein H1/H2 (hnRNP H2), and/or heterogeneous nuclear ribonuclear protein A2/B1 (hnRNP A2/B1). The invention additionally provides a method for identifying compounds active against melanoma cells.
Type:
Grant
Filed:
December 15, 2017
Date of Patent:
October 19, 2021
Assignees:
Nova Southeastern University, Auburn University, Florida Atantic University Board Of Trustees, Torrey Pines Institute for Molecular Studies
Inventors:
Dmitriy Minond, Gregg B. Fields, Marcello Giulianotti